Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesTranscode Therapeutics Inc

Transcode Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.49 USD -0.02 ( 1.32%)
Last update at 2026-11-06T21:00:00Z
VOLUME
12777
Market Cap
11.85M

Momentum Score

…

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.45
Low
1.56
High
52 Week Price Range
0.42
Low
223.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Transcode Therapeutics Inc. (RNAZ) is limited; available filings and company materials do not provide a detailed, verifiable description of its core business, pipeline, or commercial activities. Because disclosures are sparse, specific long-term growth drivers and reasons investors may find the company attractive cannot be reliably determined from public sources.
Material investment risks include limited public disclosure, likely early-stage or pre-revenue status with financing and execution risk, and significant regulatory and clinical-development uncertainty.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.51
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.27
ROE
-784.63%
Net Debt
-2.32M
ROCE
-1111.65%
Diluted EPS TTM
-3885.98

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -17.56M -6.84M -2.34M -0.61M -
Net income -35.13M -6.94M -2.74M -0.76M -
Selling general administrative 8.43M 3.40M 0.44M 0.23M -
Reconciled depreciation 0.10M 0.04M - - -
Ebit -18.67M -6.15M -0.73M -0.46M -0.38M
Ebitda -17.47M -5.83M -0.73M -0.46M -
Depreciation and amortization 1.20M 0.32M 0.00M 0.00M -
Operating income -18.67M -6.15M -0.73M -0.46M -
Other operating expenses 17.59M 5.87M 0.73M 0.46M -
Interest expense 17.56M 0.10M 0.39M 0.16M 0.00M
Tax provision - - 0.00M 0.00M -
Interest income 0.02M 0.00M 0.00M 0.00M -
Net interest income 0.02M -0.09M -0.39M -0.16M -
Income tax expense 17.56M 0.10M 0.39M 0.16M -
Total revenue 0.00M 0.00M 0.00M 0.00M -
Total operating expenses 17.59M 5.87M 0.73M 0.46M -
Total other income expense net 1.10M -0.69M -1.62M -0.15M -
Net income from continuing ops -17.56M -6.84M -2.34M -0.61M -
Net income applicable to common shares -17.56M -6.84M -2.34M -0.61M -0.45M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 5.17M 7.59M 22.94M 1.06M 0.20M
Other current assets 1.69M 1.50M 1.84M 0.00M -
Total liab 3.53M 4.35M 2.53M 4.46M 1.31M
Total stockholder equity 1.64M 3.24M 20.40M -3.41M -1.11M
Deferred long term liab - - - 0.22M -
Other current liab 0.72M - 2.50M 0.40M 0.06M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -46.42M -27.87M -10.31M -3.46M -1.12M
Other liab - - - 1.97M 0.32M
Other assets 0.00M - - 0.22M -
Cash 2.77M 4.97M 20.83M 0.83M 0.20M
Total current liabilities 3.49M 4.35M 2.53M 0.40M 0.06M
Current deferred revenue 0.03M - 0.03M - -
Net debt -2.32M -4.97M -20.83M 1.26M 0.72M
Short term debt 0.41M - - - -
Short long term debt total 0.45M - - 2.09M 0.93M
Other stockholder equity 48.06M 31.11M 30.71M 0.05M 0.01M
Property plant equipment - - 0.21M - -
Total current assets 4.46M 7.38M 22.73M 0.83M 0.20M
Net tangible assets - 3.24M 20.40M -3.41M -1.11M
Net receivables - 0.36M - - -
Long term debt - - - 2.09M 0.93M
Inventory - 0.55M - - -
Accounts payable 2.33M 4.35M - - -
Accumulated other comprehensive income 0.00M - - - -
Common stock total equity - - - 0.00M 0.00M
Non currrent assets other 0.11M - - 0.22M -
Non current assets total 0.71M 0.21M 0.21M 0.22M 0.00M
Capital lease obligations 0.45M - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.10M -0.25M - - -
Change to liabilities 1.84M 2.32M 0.19M -0.05M 0.06M
Total cashflows from investing activities - -0.25M -0.25M -0.25M -0.25M
Net borrowings - - 1.19M 0.50M 0.55M
Total cash from financing activities 0.01M 25.52M 1.12M 0.50M 0.51M
Change to operating activities - -1.85M 0.12M 0.05M 0.02M
Net income -17.56M -6.84M -2.34M -0.61M -0.45M
Change in cash -15.86M 20.00M 0.62M -0.01M 0.21M
Begin period cash flow 20.83M 0.83M 0.20M 0.21M -
End period cash flow 4.97M 20.83M 0.83M 0.20M 0.21M
Total cash from operating activities -15.76M -5.27M -0.49M -0.51M -0.30M
Issuance of capital stock 0.00M 26.34M - - -
Depreciation 0.10M 0.04M 0.04M 0.04M 0.04M
Other cashflows from financing activities -5.98M -0.82M 1.12M 0.50M -0.04M
Change to netincome - 1.07M 1.54M 0.10M 0.07M
Capital expenditures 0.10M 0.25M 0.25M 0.25M 0.25M
Change in working capital 1.31M 0.43M 0.31M -0.00M -
Stock based compensation 0.40M 0.19M 0.05M 0.00M -
Other non cash items - 0.04M 1.50M 0.10M -
Free cash flow -15.86M -5.52M -0.49M -0.51M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
RNAZ
Transcode Therapeutics Inc		 -0.02
1.32%		 1.49 - - - 2.20 -0.07
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Transcode Therapeutics Inc

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.

6 Liberty Square, Boston, MA, United States, 02109

857 837 3099

https://www.transcodetherapeutics.com

10

Name Title Year Born
Mr. Robert Michael Dudley Co-Founder, CEO, Pres & Director 1951
Mr. Thomas A. Fitzgerald M.B.A. CFO, VP of Admin. & Director 1952
Dr. Zdravka Medarova Ph.D. Co-Founder & CTO 1975
Dr. Anna Moore Ph.D. Co-Founder, Scientific Advisor & Member of Scientific Advisory Board 1962
Dr. Qiyong Peter Liu Ph.D. VP of R&D and Chief Scientist 1964
Mr. Alan Freidman VP of Investor Relations NA
Mr. Thomas A. Fitzgerald M.B.A. Interim CEO, CFO, President, VP of Administration & Director 1952
Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. Executive Chairman of the Board 1959
Dr. Zdravka Medarova Ph.D. Co-Founder & Chief Scientific Officer 1975
Ms. Susan Duggan M.B.A., R.N. Senior Vice President of Operations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…